**Alert**

If the patient has ANY adverse reaction, stop infusion and call a medical officer IMMEDIATELY.

This formulary is for Intragam 10.

Intragam 10 is the domestically produced intravenous immunoglobulin (IVIg) and is the most likely product that you will receive from the Australian Blood Service.

Intragam P (6%) is no longer produced as of June 2018.

Flebogamma 5% and 10% should not be given to neonates due to undiagnosed hereditary fructose intolerance.

Other preparations such as Privigen 10 are available for paediatric use, but beyond the scope of this formulary.

**Indication**

1. Neonatal alloimmune thrombocytopenia (NAIT)
2. Haemolytic disease of the newborn (HDN) (isoimmunisation)
3. Immune thrombocytopenic purpura
4. Primary immunodeficiency diseases
5. Secondary hypogammaglobulinaemia
6. Neonatal haemochromatosis – gestational alloimmune liver disease (GALD)
7. Neonatal myasthenia gravis
8. Severe neonatal enterovirus infection including myocarditis or hepatitis
9. Sepsis/infection – prevention and treatment – NOT RECOMMENDED.

1, 3-5, and 7 are approved indications by the National Blood Authority of Australia, 6 is a proposed addition as of June 2018.


**Action**

Immunoglobulin G (IgG) provides humoral immunity and is an immune modulator. [19]

**Drug Type**

Immunoglobulin

**Trade Name**

Intragam 10. Contains 1 g of immunoglobulin G in 10 mL.

**Presentation**

Intragam 10 is a 10% w/v solution of IgG produced by CSL Behring from voluntary donors to the Australian Red Cross. Intragam® 10 comes in 2.5 g in 25 mL, 10 g in 100 mL and 20 g in 200 mL. All these strengths provide 1 g of Ig in 10 mL.

Donors are screened for antibodies to HIV and Hepatitis B and C.

**Dosage / Interval**

Medical officer should prescribe (1) brand of IVIg and the % concentration (e.g. Intragam 10), (2) dose in grams and the volume in mL (e.g. 2 g/20 mL) and (3) Rate of infusion (see Administration section)

**Isoimmunisation:**

1 g/kg (range 0.5–1.5 g/kg) IV. Dose may be repeated in 12–24 hours if required.

**Neonatal alloimmune thrombocytopenia (NAIT):**

1 g/kg IV. Repeat if required.

**Immune thrombocytopenic purpura (ITP):**

1 g/kg IV. Repeat if required.

**Immunodeficiency:**

0.4 g/kg IV (dose should be based on number of infections and trough serum IgG concentration [optimally above 6 g/L, higher if there is bronchiectasis]).

**Neonatal myasthenia gravis:**

1 g/kg IV daily for 2 days (total dose: 2 g/kg). If additional therapy required, titrate against clinical response.[9]

**Severe enterovirus infection/myocarditis or hepatitis:**
<table>
<thead>
<tr>
<th>Intravenous Immunoglobulin</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIG</td>
<td></td>
</tr>
<tr>
<td>For newborn use only</td>
<td></td>
</tr>
</tbody>
</table>

**Maximum daily dose**

- 2 g/kg IV (up to 2.5 g/kg) as a single dose within 3 days of onset.
- **Sepsis/infection (prevention or treatment) – not recommended:**
  - 0.5 to 1 g/kg IV repeated at intervals when required has been used.
- **Neonatal haemochromatosis:**
  - 1–2 g/kg/day IV following exchange transfusion in the first 7 days and then 1 g/kg weekly, as required.

**Route**

- Intravenous.

**Preparation/Dilution**

- Obtain written consent from parent or guardian.
- All opened bottles must be used immediately.
- Do not shake bottles to avoid foaming.
- A ‘peel-off’ identification label with Batch Number and Expiry Date is to be placed on the patient’s Blood Component order form.
- Allow preparation to reach room temperature and inspect for turbidity or sediments. If seen, return to Blood Bank.

**Administration**

- Infusion rate: 0.5 mL/kg/hour for 60 minutes; then 1 mL/kg/hour for next 60 minutes; 2 mL/kg/hour for next 60 minutes; then 4 mL/kg/hour (at a maximum rate of 25 mL/hour).
- To be checked by two Registered Nurses.
  - Requires a surgically clean procedure.
  - Given via intravenous cannula, central line, long line or port.
  - Administered by infusion pump.
  - A blood filter is not required, but may be used.
  - Sodium chloride 0.9% may be used as a flush at the end of the infusion.

**Monitoring**

- Vital sign monitoring of temperature, heart rate, respiratory rate and blood pressure to be recorded before commencement of infusion.
- If the patient is unwell or there are any concerns particularly regarding the baseline observations, the medical officer should be contacted before the infusion commences.
- Vital signs (temperature, heart rate, respiratory rate) should then be checked and recorded:
  - Within 15 minutes after the start of the infusion;
  - Hourly during the infusion;
  - At the end of the infusion.

**Contraindications**

- Patients who have had an anaphylactic reaction to a human immunoglobulin preparation.

**Precautions**

**Drug Interactions**

- Concurrent use of immunoglobulin and live virus vaccines may result in interference with the immune response to the live vaccine. The Australian Technical Advisory Group on Immunisation (ATAGI) recommendations are below:
  - **Hepatitis B vaccine** is an inactivated vaccine and can be administered at any time before, after or concurrently with IVIg.
  - **Rotavirus vaccine** may be administered at any time before, after or concurrently with any blood product, including antibody-containing products.
  - **BCG vaccine** can be given at any time before or after administration of immunoglobulin or any antibody-containing blood product.
  - Following the receipt of IVIg for ITP treatment, an interval of 8–10 months should elapse before vaccination with an MMR, MMRV or varicella vaccine.
- May result in false-positive Coombs test due to passive transmission of antibodies to erythrocyte antigens.
- May result in a falsely elevated blood glucose measurement due to assay interference with the glucose dehydrogenase (pyrroloquinoline-quinone) method.
### Adverse Reactions

If adverse reactions occur, the first response should be to stop the infusion, then notify Medical Officer.

- Severe reactions are uncommon especially in neonates. In older patients are most likely to occur during the first infusion, but may occur subsequently.
- Anaphylactic reactions are rare: urticaria, angioedema, bronchospasm and hypotension. Anaphylactic reactions may require oxygen, adrenaline (epinephrine) and steroids depending on severity of the reaction.
- More common reactions are: flushing, fever, headache, pallor, shivering and tachycardia.
- Other reported reactions: dyspnoea, chest tightness, tachycardia or hypotension without anaphylaxis, transient haemolytic anaemia, abdominal pain and renal failure.
- Milder reactions often resolve after the infusion has been stopped. If so, after discussion with medical staff, the infusion may be recommenced at a slower rate after at least 15 minutes.
- Subsequent infusions should be commenced and escalated at a slower rate.

### Compatibility

Sodium chloride 0.9% for priming and flushing. Others not tested. Administer through a separate line.

### Incompatibility

Compatibility with other drugs not established.

### Stability

Do not mix immunoglobulin products of different formulations or from different manufacturers.

### Storage

Store at 2 to 8 °C (Refrigerate. Do not freeze). Protect from light.

Once removed from refrigeration, unopened bottles of Intragam 10 must be used within three months.

Intragam 10 can only be ordered from the Australian Red Cross Blood Service (ARCBS).

### Special Comments

Newborn infants with isoimmunisation who are considered at risk of exchange transfusion must have intensive prophylactic phototherapy as this is the intervention most likely to prevent the need for exchange transfusion.

If not yet done – newborn screening (NBS) should be performed prior to infusion and repeated as per blood transfusion/NBS policy.

### Evidence summary

Refer to full version.

### References

Refer to full version.

---

**Original version Date:** 3/07/2018  
**Author:** NMF Consensus Group

**Current Version number:** 1.0  
**Current Version Date:** 03/07/2018

**Risk Rating:** High  
**Due for Review:** 03/07/2020

**Approval by:** JHCH CQ&PCC  
**Approval Date:** 24/07/2018

---

**Authors Contribution**

<table>
<thead>
<tr>
<th>Original author/s</th>
<th>David Osborn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision author/s</td>
<td></td>
</tr>
<tr>
<td>Expert review</td>
<td>Helen Lily, Gemma Crighton, Diana Moore</td>
</tr>
<tr>
<td>Evidence Review</td>
<td>David Osborn</td>
</tr>
<tr>
<td>Nursing Review</td>
<td>Eszter Jozsa, Robyn Richards</td>
</tr>
<tr>
<td>Pharmacy Review</td>
<td>Jing Xiao, Cindy Chen, Carmen Burman</td>
</tr>
<tr>
<td>NMF Group contributors</td>
<td>Nilkant Phad, Himanshu Popat, Michael Hewson, Arun Sasi, Roland Broadbent</td>
</tr>
<tr>
<td>Final content and editing review of the original</td>
<td>Ian Whyte</td>
</tr>
<tr>
<td>Electronic version</td>
<td>Cindy Chen, Ian Callander</td>
</tr>
<tr>
<td>Facilitator</td>
<td>Srinivas Bolisetty</td>
</tr>
</tbody>
</table>